Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) – Equities research analysts at Oppenheimer Holdings lowered their Q3 2017 earnings per share (EPS) estimates for Synergy Pharmaceuticals in a research note issued to investors on Thursday. Oppenheimer Holdings analyst D. Archila now anticipates that the biopharmaceutical company will post earnings of ($0.21) per share for the quarter, down from their prior forecast of ($0.20). Oppenheimer Holdings has a “Buy” rating and a $9.00 price target on the stock. Oppenheimer Holdings also issued estimates for Synergy Pharmaceuticals’ Q4 2017 earnings at ($0.18) EPS, FY2017 earnings at ($0.90) EPS, FY2018 earnings at ($0.50) EPS, FY2019 earnings at ($0.26) EPS, FY2020 earnings at $0.00 EPS and FY2021 earnings at $0.27 EPS.

A number of other research analysts also recently weighed in on SGYP. Zacks Investment Research downgraded Synergy Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Canaccord Genuity restated a “buy” rating and issued a $13.00 price target on shares of Synergy Pharmaceuticals in a research note on Monday, July 10th. Citigroup Inc. restated a “sell” rating and issued a $3.70 price target on shares of Synergy Pharmaceuticals in a research note on Wednesday, June 28th. BTIG Research restated a “buy” rating and issued a $11.00 price target on shares of Synergy Pharmaceuticals in a research note on Tuesday, June 27th. Finally, BidaskClub upgraded Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $10.67.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/07/18/oppenheimer-holdings-weighs-in-on-synergy-pharmaceuticals-inc-s-q3-2017-earnings-sgyp.html.

Shares of Synergy Pharmaceuticals (SGYP) opened at 4.35 on Monday. The company has a 50-day moving average price of $4.05 and a 200 day moving average price of $4.99. The firm’s market capitalization is $978.53 million. Synergy Pharmaceuticals has a 12-month low of $3.34 and a 12-month high of $7.15.

Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The company had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.10 million.

Several hedge funds have recently added to or reduced their stakes in SGYP. Tudor Investment Corp Et Al boosted its stake in Synergy Pharmaceuticals by 1.3% in the fourth quarter. Tudor Investment Corp Et Al now owns 18,376 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 232 shares during the last quarter. Amalgamated Bank boosted its stake in Synergy Pharmaceuticals by 7.9% in the first quarter. Amalgamated Bank now owns 24,013 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,758 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Synergy Pharmaceuticals by 12.9% in the first quarter. Principal Financial Group Inc. now owns 37,343 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 4,267 shares during the last quarter. Legal & General Group Plc boosted its stake in Synergy Pharmaceuticals by 12.2% in the first quarter. Legal & General Group Plc now owns 49,476 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 5,367 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in Synergy Pharmaceuticals by 27.4% in the first quarter. Janney Montgomery Scott LLC now owns 30,200 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 6,500 shares during the last quarter. 67.37% of the stock is owned by institutional investors.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Earnings History and Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.